Abgenix, Inc. (ABGX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (60)	11/20/2001 10:16:01 AM
From: Icebrg	Read Replies (2) of 590

Robbie Stephens' impressions from yesterdays CC. It is really a pity that the conference is not available over the Internet. I would have liked to listen to it. Ice Abgenix, Inc [NASDAQ: ABGX $33.97] 12-Month Price Target: $61.00 2001E EPS: ($0.73) 2002E EPS: ($0.99) Strong Buy Michael King, Biopharmaceuticals Investment Conclusion: Abgenix's management outlined an ambitious strategy for moving antibodies into and through clinical trials during a conference call update. Management also described two promising antibodies that may enter clinical trials in 2002. We continue to believe that Abgenix will become a leader in developing antibody therapeutics and reiterate our Strong Buy rating and 12-month target price of $61.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next